TALIGEN THERAPEUTICS
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
TALIGEN THERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2004-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.taligentherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
617-444-8443
Email Addresses:
[email protected]
Total Funding:
78.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Font Awesome Mobile Non Scaleable Content LiteSpeed Hetzner
Current Employees Featured
Founder
Investors List
Alta Partners
Alta Partners investment in Series B - Taligen Therapeutics
Sanderling Ventures
Sanderling Ventures investment in Series B - Taligen Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Taligen Therapeutics
High Country Venture
High Country Venture investment in Series B - Taligen Therapeutics
Alta Partners
Alta Partners investment in Series B - Taligen Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Taligen Therapeutics
High Country Venture
High Country Venture investment in Series B - Taligen Therapeutics
Sanderling Ventures
Sanderling Ventures investment in Series B - Taligen Therapeutics
University License Equity Holdings
University License Equity Holdings investment in Series A - Taligen Therapeutics
High Country Venture
High Country Venture investment in Series A - Taligen Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-09-26 | Qualigen Therapeutics appoints Kevin Richardson as Interim CEO and CFO |
Official Site Inspections
http://www.taligentherapeutics.com
Unable to get host informations!!!
More informations about "Taligen Therapeutics"
Taligen Therapeutics - Crunchbase Company Profile
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement …See details»
Taligen Therapeutics Headquarters - StartUp Web Solutions
Headquarters 245 1st Street,Suite 1100,Cambridge, MA 02142 Type of Company Private Industries Pharmaceuticals Medical Support Services Company Description Taligen …See details»
Alexion Acquires Taligen Therapeutics and Creates Translational ...
Jan 31, 2011 Taligen's scientific staff will form the nucleus of Alexion's new Cambridge Massachusetts-based Translational Medicine Group, headed by Abbie Celniker, Ph.D., former …See details»
Taligen Therapeutics Inc., Woodruff Emlen,
[email protected]: Phone: 1-720-859-4056: Website: www.taligentherapeutics.com Fax: 1-720-859-4110: Summary ; Executive Details ; Board Members ; Business Information …See details»
Taligen Therapeutics - Company Profile - Tracxn
Taligen Therapeutics developed protein therapeutics for inflammatory diseases. Its therapies modulated the alternative pathway of the complement system to treat a wide range of …See details»
Taligen Therapeutics - Products, Competitors, Financials, …
Alexion Pharma Gobbles Up Taligen in $111M Buyout. Jan 31, 2011. XconomyBoston — There’s big news for Taligen Therapeutics this morning. Cheshire, CT-based Alexion Pharmaceuticals …See details»
Taligen Therapeutics - Headquarter Location, Corporate Office …
Taligen Therapeutics is Drug Discovery in United States that focus on Provider business. Founded in 2004. They cover business area such as Provider, development stage …See details»
Taligen Therapeutics 2025 Company Profile: Valuation, …
Taligen Therapeutics General Information Description. Provider of development stage biotechnology services for the treatment of inflammatory diseases. The company is developing therapies that regulate the complement system to treat …See details»
Nextsource | Company Profile | Taligen Therapeutics
Explore the company profile of Taligen Therapeutics (taligentherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Alexion Pharmaceuticals Inc. Acquires Taligen Therapeutics
Jan 31, 2011 CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. announced that it has acquired Taligen Therapeutics, Inc., a privately held development-stage …See details»
Taligen Therapeutics - Ownership and Business Overview - Mergr
Taligen Therapeutics was founded in 2004. Life Science M&A Summary in 2011 Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2011 .See details»
Taligen Therapeutics - Contacts, Employees, Board Members, …
Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases. New. Resources. Advanced Search. ... Log In. …See details»
Taligen Therapeutics - Crustdata Company Profile, Funding and …
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of …See details»
Taligen Therapeutics Overview | SignalHire Company Profile
Organization Website: taligentherapeutics.com : Taligen Therapeutics industries Biotech: Taligen Therapeutics Employees Size 10-50 employees: Taligen Therapeutics headquarters is in …See details»
Taligen Therapeutics - VentureRadar
Acquired by Alexion Pharmaceuticals in January 2011 for $111 million. ... Find out more about Taligen Therapeutics, Biotech.See details»
CU licensee acquired by Alexion Pharma in buyout
Feb 8, 2011 Taligen Therapeutics, a licensee of the University of Colorado, was acquired recently by Cheshire, Conn.-based Alexion Pharmaceuticals for $111 million and contingent …See details»
Alexion Pads Biologic R&D with $111M Acquisition of Taligen
Jan 31, 2011 Company obtains preclinical-stage protein and antibody therapies. Alexion Pharmaceuticals acquired Taligen Therapeutics for $111 million, gaining preclinical-stage …See details»
Taligen Therapeutics - Funding, Financials, Valuation & Investors
Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases. New. Resources. Advanced Search. ... How much …See details»
Taligen Therapeutics, Inc. - OpenGovCO
Taligen Therapeutics, Inc. (Entity# 19951070191) is a business corporation registered with Colorado Department of State (CDOS). The business formed date is May 30, 1995. ... Agent …See details»
Alexion snaps up Taligen for $111M-plus, creates translational unit
Jan 31, 2011 The promising protein drug developer Taligen Therapeutics is being snapped up by Alexion Pharmaceuticals for $111 million upfront and an undisclosed package of milestones …See details»